RPG Life Sciences (RPGLS), the life sciences and medicine component research and manufacturing arm of the RPG Group, is looking at a private equity placement.
“We are planning to set up a special purpose vehicle and are in talks with private equity players now. We will explore non-equity routes to get investments in the company,” said Arvind Vasudeva, managing director, RPG Life Sciences.
The company, which is emerging from a major internal and financial restructuring exercise over the last two years, would require Rs 100 crore in capital expenditure over the next five years.
It will also sell off parts of its assets, including some land and technology capabilities to raise cash, Vasudeva said.
The company is working on an expansion in its medicine portfolio. It has three medicine active pharmaceutical ingredients, in immunology, and has three more in oral forms. It also has three cancer drugs, and are working on 10 more.